{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:16:53Z","timestamp":1792163813859,"version":"4.4.0"},"reference-count":26,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2008,7,17]],"date-time":"2008-07-17T00:00:00Z","timestamp":1216252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:p>To evaluate acute onset of anxiolytic activity using a dental anxiety model, 89 patients were randomised to double-blind single dose pregabalin 150 mg, alprazolam 0.5 mg or placebo 4 h before a scheduled dental procedure. A Dental Anxiety Total score &gt;12 (moderate-to-severe) without meeting Diagnostic and Statistical Manual of Mental Disorders (Fourth edition) (DSM-IV) anxiety disorder criteria was required. Efficacy and safety, assessed 2, 2.5, 3, 3.5 and 4 h postdose, included 100 mm Visual Analogue Scale for Anxiety (VAS-Anxiety; primary outcome), 100 mm VAS-Sedation and Time-to-Onset of Action Scale (TOAS), a patient-rated anti-anxiety drug-benefit scale (no [0] to full benefit [10]). Mixed model analysis found significantly greater VAS-A improvement slopes for pregabalin (t = \u22122.47; P = 0.014) and alprazolam (t = \u22122.39; P = 0.018). There was a significant improvement versus placebo in the TOAS from 2 h through endpoint in alprazolam patients and from 3 h onward in pregabalin patients. Pregabalin produced significantly greater increases in VAS-Sedation versus placebo from 2.5 h through 4 h (2 h onward for alprazolam). Notably, there was a higher correlation between TOAS and VAS-Sedation (r = +0.58) than VAS-Anxiety (r = \u22120.50) on Spearman\u2019s analysis. The majority of Adverse Effects (AEs) were mild, and the most frequent for pregabalin, alprazolam, and placebo, respectively, were fatigue (N = 7, 7, 3), dizziness (N = 6, 3, 3), attention disturbance (N = 3, 1, 0), somnolence (N = 3, 0, 0), feeling abnormal (N = 0, 2, 0) and balance disorder (N = 0, 2, 0). These results suggest that onset of clinically meaningful anxiolytic effect after single-dose pregabalin occurs within the first 3\u20144 h. Additional research is needed to determine whether anxiolytic effect occurs in generalized anxiety disorder populations by day 1 or within 3\u20144 h post-first dose.<\/jats:p>","DOI":"10.1177\/0269881108094722","type":"journal-article","created":{"date-parts":[[2008,7,17]],"date-time":"2008-07-17T21:26:04Z","timestamp":1216329964000},"page":"867-873","source":"Crossref","is-referenced-by-count":32,"title":["Early onset anxiolytic efficacy after a single dose of pregabalin: double-blind, placebo- and active-comparator controlled evaluation using a dental anxiety model"],"prefix":"10.1177","volume":"23","author":[{"given":"D.","family":"Nutt","sequence":"first","affiliation":[{"name":"Psychopharmacology Unit, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mandel","sequence":"additional","affiliation":[{"name":"Clinical R&D, Statistics, Pfizer Inc, New York, USA,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Baldinetti","sequence":"additional","affiliation":[{"name":"Global Medical, Neuroscience, Pfizer Inc, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2008,7,17]]},"reference":[{"issue":"11","key":"atypb1","first-page":"53","volume":"62","author":"Ballenger, JC","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1016\/S1079-2104(97)90055-X"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.14219\/jada.archive.1993.0233"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000150932.48688.BE"},{"issue":"3","key":"atypb5","first-page":"A421","volume":"54","author":"Bockbrader, HN","year":"2000","journal-title":"Neurology"},{"issue":"6","key":"atypb6","first-page":"58","volume":"39","author":"Busch, JA","year":"1998","journal-title":"Epilepsia"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1177\/00220345690480041801"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1002\/art.20983"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2006.12.006"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000068024.20285.65"},{"key":"atypb11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2005.02.032"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198916060-00002"},{"key":"atypb13","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000200150.79850.8d"},{"key":"atypb14","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244106"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1053\/eujp.2001.0235"},{"key":"atypb16","volume-title":"Dataview data on market share of anxiolytic medication for third quarter","author":"IMS","year":"2005"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000145767.36287.A1"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.7.15.2139"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0511"},{"key":"atypb20","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000155820.74832.b0"},{"key":"atypb21","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.9.1022"},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1522-7154(1996)2:1<40::AID-ANXI6>3.0.CO;2-H"},{"key":"atypb23","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200204000-00016"},{"key":"atypb24","doi-asserted-by":"publisher","DOI":"10.1002\/da.20089"},{"key":"atypb25","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004269105"},{"key":"atypb26","doi-asserted-by":"publisher","DOI":"10.1159\/000139107"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881108094722","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881108094722","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:05:26Z","timestamp":1777507526000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269881108094722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,17]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1177\/0269881108094722"],"URL":"https:\/\/doi.org\/10.1177\/0269881108094722","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,17]]}}}